

## Biopsy and Histological Evaluation in Cervical Cancer Detection

Galica Jones\*

University of Geneva, Department of Pediatrics, Gynecology and Obstetrics, Switzerland

### Abstract

Biopsy and histological evaluation play a pivotal role in the detection and diagnosis of cervical cancer, providing essential information for treatment planning and prognosis. Cervical biopsy techniques, including punch biopsy, endocervical curettage, and cone biopsy, enable precise tissue sampling for histopathological examination. Histological evaluation distinguishes between precancerous lesions and invasive carcinoma, facilitating appropriate clinical interventions. This article explores the significance of biopsy and histological assessment in cervical cancer detection, highlighting diagnostic accuracy, challenges, and advancements in pathological evaluation. By emphasizing the importance of early diagnosis, histological grading, and emerging biomarkers, this paper underscores the role of histopathology in reducing cervical cancer mortality rates.

**Keywords:** Cervical cancer; Biopsy; Histological evaluation; Histopathology; Screening; Diagnosis; Cervical intraepithelial neoplasia

### Introduction

Cervical cancer remains a major global health burden, particularly in regions with inadequate screening programs. Early detection through effective diagnostic methods is crucial for improving survival rates and preventing disease progression. Biopsy and histological evaluation serve as gold standards for diagnosing cervical cancer, allowing precise classification of neoplastic changes. The histopathological assessment differentiates between low-grade and high-grade cervical intraepithelial neoplasia (CIN) and invasive carcinoma, guiding clinical management [1-3].

This article examines the role of cervical biopsy techniques and histological evaluation in cervical cancer detection. It explores the different biopsy methods, the histopathological classification of cervical cancer, and the clinical implications of accurate diagnosis. By improving diagnostic accuracy and implementing advanced pathological techniques, healthcare providers can enhance patient outcomes and reduce the global cervical cancer burden [4,5].

### Description

#### Types of cervical biopsies

Cervical biopsy involves the extraction of cervical tissue for histopathological analysis. The main types include:

- **Punch biopsy:** A commonly used method in colposcopy-guided assessment; small tissue samples are obtained from suspicious cervical lesions.
- **Endocervical curettage (ECC):** Used to collect tissue from the endocervical canal when colposcopic examination is inconclusive.
- **Cone biopsy (Conization):** Includes Loop Electrosurgical Excision Procedure (LEEP) and cold knife conization; used for excisional diagnosis and treatment of high-grade lesions.
- **Needle biopsy:** Less common, but used when deeper tissue sampling is required.

#### Indications for Cervical Biopsy

- Abnormal Pap smear results (ASC-H, HSIL, or AGC findings).

- Positive high-risk HPV test.
- Suspicious cervical lesions observed during colposcopy.
- Unexplained abnormal vaginal bleeding.
- Monitoring of previously diagnosed CIN.

### Histological evaluation of cervical cancer

#### Histopathological classification

Histological evaluation differentiates between benign, pre-malignant, and malignant cervical lesions. The primary classifications include [6].

#### Cervical intraepithelial neoplasia (CIN):

**CIN 1 (Low-grade dysplasia):** Confined to the lower third of the epithelium, often regresses.

**CIN 2 (Moderate dysplasia):** Affects two-thirds of the epithelial thickness, requiring intervention.

**CIN 3 (Severe dysplasia and carcinoma in situ):** Full-thickness epithelial involvement, high risk of progression to invasive cancer.

**Squamous cell carcinoma (SCC):** Accounts for approximately 80% of cervical cancers; characterized by malignant transformation of squamous epithelial cells [7].

**Adenocarcinoma:** Originates from glandular epithelium; associated with high-risk HPV strains and more aggressive behavior.

**Adenosquamous carcinoma:** A mixed histological subtype with both squamous and glandular components.

**\*Corresponding author:** Galica Jones, University of Geneva, Department of Pediatrics, Gynecology and Obstetrics, Switzerland, E-mail: joneslica425@yahoo.com

**Received:** 01-Feb-2025, Manuscript No: ccoa-25-163379, **Editor Assigned:** 04-Feb-2025, pre QC No: ccoa-25-163379 (PQ), **Reviewed:** 18-Feb-2025, QC No: ccoa-25-163379, **Revised:** 22-Feb-2025, Manuscript No: ccoa-25-163379 (R), **Published:** 27-Feb-2025, DOI: 10.4172/2475-3173.1000254

**Citation:** Galica J (2025) Biopsy and Histological Evaluation in Cervical Cancer Detection. Cervical Cancer, 10: 254.

**Copyright:** © 2025 Galica J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Role of biomarkers in histological assessment

**p16INK4a:** A surrogate marker for high-risk HPV-associated neoplasia, used to differentiate CIN 2/3 from benign lesions.

**Ki-67:** A proliferation marker used to assess cell cycle activity in cervical dysplasia.

**HPV DNA testing:** Complements histological evaluation in identifying high-risk HPV involvement [8-10].

Discussion

Diagnostic accuracy and challenges

**Sensitivity and specificity:** Histological evaluation provides high diagnostic accuracy but requires expert interpretation.

**Inter observer variability:** Differences in pathologist interpretation may lead to discrepancies in CIN grading.

**Sampling errors:** Inadequate biopsy specimens may result in underdiagnosis or misclassification.

**Technological advancements:** Digital pathology and artificial intelligence-assisted image analysis are improving diagnostic precision.

Clinical implications of histopathological findings

Histological findings determine the appropriate management approach:

**CIN 1:** Conservative management with follow-up Pap smears and HPV testing.

**CIN 2/3:** Requires excisional treatment (LEEP or conization) to prevent progression to invasive cancer.

**Invasive cancer:** Treatment depends on staging and may involve surgery, radiation, and chemotherapy.

Impact of histopathology on patient outcomes

**Early and accurate diagnosis:** Reduces mortality and morbidity by enabling timely treatment.

**Risk stratification:** Helps in determining the need for close surveillance or aggressive intervention.

**Guidance for personalized therapy:** Molecular profiling of biopsied tissue may inform targeted therapeutic strategies.

Conclusion

Biopsy and histological evaluation remain indispensable tools

in cervical cancer detection and management. These diagnostic methods provide critical insights into the nature and progression of cervical lesions, ensuring appropriate clinical interventions. Emerging histopathological techniques, including molecular biomarkers and AI-driven diagnostics, are enhancing diagnostic accuracy and patient outcomes.

By prioritizing routine cervical screening, timely biopsy, and precise histological assessment, healthcare providers can significantly reduce the global burden of cervical cancer. Strengthening awareness, improving access to diagnostic services, and advancing histopathological research will further improve early detection and treatment success rates.

Acknowledgement

None

Conflict of Interest

None

References

1. Busch A, Jäger M, Mayer C, Sowislok A (2021) Functionalization of Synthetic Bone Substitutes. *Int J Mol Sci* 22: 4412
2. Jayash S, Al-Namnam NM, Shaghayegh G (2020) Osteoprotegerin (OPG) pathways in bone diseases and its application in therapeutic perspectives. *Biointerface Res Appl Chem* 10: 5193-5200.
3. Altieri B, Di Dato C, Martini C, Sciammarella C, Di Sarno A (2019) Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management. *Cancers* 11: 1332.
4. Menéndez S, Gallego B, Murillo D, Rodríguez A, Rodríguez R, et al. (2021) Cancer Stem Cells as a Source of Drug Resistance in Bone Sarcomas. *J Clin Med* 10: 2621.
5. Rajani R, Gibbs CP (2012) Treatment of Bone Tumors. *Surg Pathol Clin* 5: 301-318.
6. Thanindratarn P, Dean DC, Nelson SD, Hornicek FJ, Duan Z, et al. (2019) Advances in immune checkpoint inhibitors for bone sarcoma therapy. *J Bone Oncol* 15: 100221.
7. Ferracini R, Martínez-Herreros I, Russo A, Casalini T, Rossi F, et al. (2018) Scaffolds as Structural Tools for Bone-Targeted Drug Delivery. *Pharmaceutics* 10: 122.
8. Cortini M, Baldini N, Avnet S (2019) New Advances in the Study of Bone Tumors: A Lesson from the 3D Environment. *Front Physiol* 10: 814.
9. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. *CA Cancer J Clin* 66: 7-30.
10. Rosati LM, Herman JM (2017) Role of Stereotactic Body Radiotherapy in the Treatment of Elderly and Poor Performance Status Patients with Pancreatic Cancer. *J Oncol Pract* 13: 157-166.